Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
bearish
Health Care
The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)
Xinyao has highlighted this Insight as a Top Pick
Thematic (Sector/Industry)
334 Views
20 Dec 2021 01:08
The article analyzed CXO plunge last week, the potential impact, the investment logic, the outlook on CXO and biotech, the scenarios when are suitable for related investment, and advice for investors.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »
China Healthcare Weekly (Jun.15) - Outlook of GLP-1 Market, WuXi Bio’s Placement, Keymed's Placement
Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
WuXi Biologics (2269 HK) - Strong Demand to Drive Growth Acceleration in 2025
Wuxi Biologics (2269 HK) - The Concerns Behind 2024 Results and the Outlook in 2025
Wuxi Biologics (2269 HK): 2024 Revenue Meets Guidance; Poised for Accelerated Growth in 2025
Trending Collections
More »
Index Rebalance
Japan
Equity Bottom-Up
Event-Driven
Philippines
India
Sell / Short Ideas
Unpaywalled Insights
South Korea
Asia Event-Driven
Trending Insights
More »
Prosus Is Elevated Vs. Tencent As The Accretion Trade Unfolds
StubWorld: Japan Post Holdings (6178 JP) Is "Cheap"
Waaree Energies (WAAREEEN IN): Increased Float & Global Index Inclusion
STAR Chip Index Rebalance Preview: Forecast Changes for September
Wuxi XDC Cayman (2268 HK): Soaring Pharma Stocks & Global Index Inclusion
Top Unpaywalled Insights
More »
Crypto Week Unleashes a Bitcoin Blitz and Sparks the Altcoin Catch-Up
The Bunny Returns: Playboy’s Market Comeback
HK Connect SOUTHBOUND Flows (To 18 July 2025); Volumes Strong, Net Buying Decent, Meituan Hot
Curator's Cut: Japan Insurers Vs Banks, the State of the Chinese EV Sector and Asian Ports in Focus
[IO Technicals 2025/29] Near Term Bullish Trend to Persist
Discussions
(Paid Plans Only)
Insight Stream
China Healthcare Weekly (Dec.24)- Capital Arbitrage, Drug Commercial Results, Healthcare Big Picture
27 Dec 2021
Guangzhou Baiyunshan Pharmaceutical Holdings (874.HK) - Conservative About the Outlook
23 Dec 2021
Pre-IPO Hangzhou Bioer Technology - Key Judgement on Performance Sustainability and Other Concerns
22 Dec 2021
The CXO/Biotech Plunge and the Afterwards Investment Logic (2022)
20 Dec 2021
Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance
09 Nov 2021
WuXi AppTec (2359.HK/603259.CH) 2021Q3 - Logic Change?
04 Nov 2021
WuXi Biologics (2269 HK) - The Strength and the Potential Risk
31 Mar 2021
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.0
x